{"id":14888,"date":"2025-10-23T20:43:37","date_gmt":"2025-10-23T15:13:37","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=14888"},"modified":"2025-12-05T11:58:01","modified_gmt":"2025-12-05T06:28:01","slug":"laurus-labs-q2-fy26-results-net-profit-soars-875-yoy-to-%e2%82%b9195-crore-revenue-up-35","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/laurus-labs-q2-fy26-results-net-profit-soars-875-yoy-to-%e2%82%b9195-crore-revenue-up-35\/","title":{"rendered":"Laurus Labs Q2 FY26 Results: Net Profit Surges 875% YoY, Revenue Grows 35%"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

Laurus Labs Ltd<\/a> reported an exceptional performance in the second quarter of fiscal year 2026 on October 23, 2025, posting significant growth across key financial parameters. The company\u2019s consolidated revenue increased by 35% year-on-year to \u20b91,653 crore, while net profit jumped 875% to \u20b9195 crore, reflecting a strong rebound in business momentum and operational efficiency.<\/p>\n

For the half-year ended September 30, 2025, consolidated revenue reached \u20b93,223 crore, up 33% compared to the same period last year. This growth was driven by robust performance across its key segments \u2014 particularly the CDMO (Contract Development and Manufacturing Organisation) and generics businesses.<\/p>\n

The company also declared an interim dividend of \u20b90.80 per share for its shareholders.<\/p>\n

<\/span>Strong Margin Expansion and Profitability<\/strong><\/span><\/h2>\n

Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) for Q2 FY26 rose by 126% to \u20b9403 crore, while EBITDA margins expanded over 1,000 basis points to 24.4%. The company\u2019s gross margin also improved by more than 4.5 percentage points to 59.6%, reflecting a favourable business mix and enhanced operational efficiency.<\/p>\n

For the half-year period, EBITDA<\/a> stood at \u20b9818 crore, registering a 132% year-on-year growth, with margins at 25.4%. Laurus Labs\u2019 management attributed the improvement to better asset utilisation, a stronger product mix, and ongoing cost optimisation measures.<\/p>\n

<\/span>Divisional Revenue Performance<\/strong><\/span><\/h2>\n

The company\u2019s CDMO division delivered outstanding growth, with Q2 revenues rising 53% year-on-year to \u20b9518 crore. Within the CDMO segment, small molecule revenues increased 58% to \u20b9471 crore, supported by strong demand and execution across projects.<\/p>\n

The generics business also performed well, recording a 28% year-on-year increase to \u20b91,135 crore during the quarter. Meanwhile, the API business grew 11%, and the Finished Dosage Form (FDF) segment rose by 58%, highlighting Laurus Labs\u2019 diversified growth momentum.<\/p>\n

For the half-year period, CDMO revenues stood at \u20b91,040 crore, up 74%, while the generics business contributed \u20b92,183 crore, a 20% increase compared to the previous year.<\/p>\n


\n\"\"
\n<\/a><\/p>\n